Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically requesting additional information from Zhejiang Shimai Pharmaceutical Co., Ltd. regarding state-owned shareholder management procedures [1] - The CSRC has outlined specific areas for Shimai Pharmaceutical to clarify, including the progress of state-owned shareholder compliance with state asset management procedures and the legality of past capital increases and share transfers [1] - The company is also required to provide details on its business scope and operations, particularly concerning compliance with foreign investment restrictions related to human stem cells and gene diagnosis and treatment technologies [1] Group 2 - The company, established in 2017, is a pioneer in next-generation T-cell engagers (TCE) therapy and is recognized as a global leader in this field [2] - TCEs are designed to target tumor cells by simultaneously binding to tumor-associated antigens (TAA) and T-cell receptors, thereby activating T-cells to induce targeted cytotoxic effects against cancer [2] - The company has developed innovative TCE therapies, including a next-generation masked TCE that can be selectively activated within tumors for the treatment of solid tumors [2]
时迈药业拟港股上市 中国证监会要求补充说明国资管理程序进展情况等事项
Zhi Tong Cai Jing·2025-12-26 14:14